XML 40 R28.htm IDEA: XBRL DOCUMENT v3.26.1
STOCKHOLDERS' EQUITY (Tables)
6 Months Ended
Jun. 30, 2026
STOCKHOLDERS’ EQUITY [Abstract]  
Schedule Common Stock Repurchase
The following table summarizes the common stock repurchase activity under the Repurchase Program:
 
                 
                     
    Three Months Ended June 30,     Six Months Ended June 30,  
     2026      2025      2026      2025  
(In thousands)
                   
Shares repurchased
  7,062    816    13,816    816 
Total cost of shares repurchased
 $45,282   $15,148   $156,362   $15,148 
Schedule of Assumptions
The following assumptions were used to determine the fair value of options granted during the six months ended June 30, 2026 and 2025:
 
         
           
    Six Month Ended June 30,  
     2026      2025  
Expected term
   5.5 - 6.3 years      5.5 - 6.3 years  
Volatility
 68%   66%
Dividend yield
  0.0    0.0 
Risk-free interest rate
   3.80 - 3.87%   4.40%
Schedule of Option Activity
The following table summarizes information about the Company’s stock options under the Company’s equity incentive plans and related information:
 
     Shares      Weighted-
Average
Exercise Price
 
Options outstanding, vested and expected to vest at December 31, 2025
 4,682,783  $6.13 
Forfeited
 (117,629)  $14.85 
Expired
   -    $-  
Granted
  695,321   $16.37 
Exercised
  (209,290  $3.25 
Options outstanding, vested and expected to vest at June 30, 2026
  5,051,185   $7.46 
           
Options exercisable
  3,250,165   $4.97 
Schedule of Unvested RSU Activity
A summary of the Company’s RSU activity and related information is as follows:
 
         
     Shares      Weighted-
Average Grant
Date Fair Value
 
Balance at December 31, 2025
  5,144,503   $9.31 
Granted
  1,297,884   $15.66 
Vested
  (1,694,229  $7.22 
Forfeited
  (206,487  $12.09 
Balance at June 30, 2026
  4,541,671   $11.77 
Schedule of Stock-Based Compensation Expense
Total stock-based compensation expense for all awards granted under the Company’s equity incentive plans for the three and six months ended June 30, 2026 and 2025 was as follows:
 
    Three Months Ended June 30,     Six Months Ended June 30,
 
(in thousands)
   2026      2025      2026      2025  
Research and development
 $75   $51   $141   $90 
Plasma center operating expenses
  143    101    266    178 
Selling, general and administrative
  4,837    3,955    9,987    7,828 
Cost of product revenue
  1,080    856    2,070    1,491 
Total stock-based compensation expense
 $6,135   $4,963   $12,464   $9,587